Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $69.3 million.

  • Ligand Pharmaceuticals' Net Cash Flow rose 5362.61% to $69.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 7138.81%. This contributed to the annual value of $50.5 million for FY2024, which is 32911.3% up from last year.
  • Ligand Pharmaceuticals' Net Cash Flow amounted to $69.3 million in Q3 2025, which was up 5362.61% from $20.1 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Net Cash Flow high stood at $69.3 million for Q3 2025, and its period low was -$60.3 million during Q2 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$1.2 million (2022), whereas its average is $4.7 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Net Cash Flow surged by 114658.31% in 2022, and later crashed by 63771.48% in 2023.
  • Ligand Pharmaceuticals' Net Cash Flow (Quarter) stood at -$3.9 million in 2021, then surged by 1146.58% to $40.9 million in 2022, then tumbled by 92.43% to $3.1 million in 2023, then surged by 230.62% to $10.2 million in 2024, then surged by 576.92% to $69.3 million in 2025.
  • Its Net Cash Flow stands at $69.3 million for Q3 2025, versus $20.1 million for Q2 2025 and -$25.3 million for Q1 2025.